Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2221-8263 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus.
Front Oncol
January 2025
Department of Oncology, Tawam Hospital, Al Ain, United Arab Emirates.
Breast cancer is the most frequently diagnosed cancer in the UAE and a leading cause of cancer-related mortality. Although early diagnosis contributes to favorable prognoses, novel treatment modalities like antibody-drug conjugates (ADCs) have significantly broadened the therapeutic landscape for patients in metastatic settings. The recognition of "HER2-low" expression as a targetable category has caused a paradigm shift in the management of breast cancer.
View Article and Find Full Text PDFEfficacy and safety of dutasteride in the treatment of alopecia: a comprehensive review.
Expert Opin Pharmacother
January 2025
Mediprobe Research Inc, London, ON, Canada.
Introduction: Alopecia affects many individuals, with androgenetic alopecia (AGA) being the most common form in both men and women. The exact etiology of AGA is unclear. The systemic treatments of AGA include 5-alpha reductase inhibitors (finasteride, dutasteride), low-dose oral minoxidil.
View Article and Find Full Text PDFMulticenter validation of secondary hemophagocytic lymphohistiocytosis diagnostic criteria.
J Intern Med
January 2025
Department of Anesthesiology and Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Background: Five fulfilled hemophagocytic lymphohistiocytosis (HLH)-2004 criteria, and the HScore are widely used and recommended by international expert consensus to diagnose secondary HLH. Both diagnostic scores have never been validated in heterogeneous patient cohorts of secondary HLH patients. We aimed to systematically optimize and validate diagnostic criteria of secondary HLH using a multicenter approach.
View Article and Find Full Text PDFDevelopment and validation of a scoring system for predicting disease activity in treatment-naïve patients with relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord
January 2025
Neurology department, Cairo University, Cairo, Egypt.
Background: Relapsing-remitting MS (RRMS) exhibits significant heterogeneity and different treatment responses. Up to date, there is no international consensus on defining disease activity which foretells potential prognosis. This study aims to develop and validate a "Scoring System for Disease Activity Prognosis in Treatment-Naïve RRMS Patients" (DAPS-RRMS) to help guiding treatment decisions.
View Article and Find Full Text PDFAntiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.
Epilepsy Behav
January 2025
Department of Neurosurgery, Mass General Brigham, Harvard Medical School, Boston, MA 02115, USA.
Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, specific electroencephalogram (EEG) patterns, and significant cognitive and behavioral impairments. To date, eight anti-seizure medications (ASMs) have been specifically approved by the U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!